RenovoRx Inc
RNXT1.220USD
+0.010+0.83%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
44.59MCap. mercado
PérdidaP/E TTM
Más Datos de RenovoRx Inc Compañía
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Información de la empresa
Símbolo de cotizaciónRNXT
Nombre de la empresaRenovoRx Inc
Fecha de salida a bolsaAug 17, 2021
Director ejecutivoMr. Shaun R. Bagai
Número de empleados10
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 17
Dirección2570 W. El Camino Real, Ste. 320,
CiudadMOUNTAIN VIEW
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94040
Teléfono14088002649
Sitio Webhttps://renovorx.com/
Símbolo de cotizaciónRNXT
Fecha de salida a bolsaAug 17, 2021
Director ejecutivoMr. Shaun R. Bagai
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Ronald B. (Ron) Kocak, CPA
Mr. Ronald B. (Ron) Kocak, CPA
Principal Financial Officer and Accounting Officer, Vice President, Controller
Principal Financial Officer and Accounting Officer, Vice President, Controller
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
Accionistas
Accionistas
Proporción
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
10.42%
Private Equity
7.09%
Investment Advisor
5.92%
Individual Investor
4.42%
Hedge Fund
3.79%
Bank and Trust
0.27%
Venture Capital
0.06%
Other
68.03%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
51
11.69M
31.97%
+5.32M
2025Q1
52
10.53M
29.46%
+6.73M
2024Q4
39
1.47M
4.14%
-2.25M
2024Q3
38
2.35M
9.16%
-392.19K
2024Q2
40
2.34M
14.23%
-1.80M
2024Q1
36
1.98M
17.38%
-1.99M
2023Q4
40
1.81M
16.91%
-1.93M
2023Q3
39
3.15M
32.01%
-2.10M
2023Q2
36
3.04M
31.03%
-2.11M
2023Q1
36
5.01M
55.46%
+3.39M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
AIGH Capital Management, LLC.
2.59M
7.09%
+2.59M
--
Mar 31, 2025
AWM Investment Company, Inc.
2.29M
6.25%
+2.29M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.35M
3.68%
+1.20M
+851.09%
Mar 31, 2025
Agah (Ramtin M.D.)
1.13M
3.1%
+21.00K
+1.89%
Jun 05, 2025
Worth Venture Partners, LLC
873.61K
2.39%
+873.61K
--
Mar 31, 2025
Alyeska Investment Group, L.P.
688.58K
1.88%
+688.58K
--
Mar 31, 2025
Bleichroeder LP
500.00K
1.37%
+500.00K
--
Mar 31, 2025
Adar1 Capital Management LLC
479.88K
1.31%
+282.63K
+143.29%
Mar 31, 2025
Geode Capital Management, L.L.C.
321.87K
0.88%
+86.13K
+36.53%
Mar 31, 2025
Bagai (Shaun R.)
320.04K
0.88%
+27.50K
+9.40%
Apr 25, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
